Swedish Orphan Biovitrum AB · eight revisions, eight raises
Eight analyst houses have updated their view on Sobi following the company's interim report on 27 October, and each of them raised their target. The median target sits 5.9 per cent above the current share price (6 November close), and the mean sits 7.1 per cent above it.
Snapshot as of 6 November 2026
All public targets
Ten analyst houses have a share price target on Sobi from the past 90 days that we were able to match to a dated notice. Eight houses set the target after Sobi's interim report of 27 October, and are included in this consensus analysis. [1]
Barclays' and Arctic Securities' targets (bottom of the table) predate the report, and are thus excluded.
| House | Previous | Target | Rec. | Last |
|---|---|---|---|---|
| Berenberg [13] | 570 | ▲600 | Buy | 3 Nov |
| HC Wainwright [10] | 575 | ▲600 | Buy | 28 Oct |
| BNP Paribas [8] | 565 | ▲575 | Buy | 28 Oct |
| Pareto Securities [6] | 480 | ▲530 | Buy | 28 Oct |
| SB1 Markets [11] | 495 | ▲525 | Buy | 29 Oct |
| DNB Carnegie [9] | 474 | ▲484 | Hold | 28 Oct |
| Nordea [7] | 450 | ▲480 | Hold | 28 Oct |
| Danske Bank [12] | 466 | ▲475 | Hold | 29 Oct |
| Barclays [14] pre-report | 530 | ▲590 | Buy | 8 Sep |
| Arctic Securities [15] pre-report | – | 551.24 | Buy | 8 Sep |
pre-report Target set before the Q3 report of 27 October 2026; listed, and excluded from the mean, median and range.
Ratings are shown normalised to Buy, Hold and Sell. BNP Paribas published Outperform, shown as Buy; Barclays published Overweight, shown as Buy.
All houses publish in Swedish kronor; no conversion has been applied.
Scroll the table sideways to see every column.
Where the panel sits
The Sobi share closed at 498.20 SEK on 6 November 2026. [2] Five of the eight included analyst targets sit above that share price and three sit below it (Danske Bank, Nordea and DNB Carnegie).
Buy · Hold · Sell
Five of the eight included houses apply a Buy rating, and three use the Hold rating. None rates it as a Sell.
Pareto Securities moved from Hold to Buy on 28 October, the only rating change since the report. [6]
Dated events behind the panel
- 2 Oct 2026Sobi completed the acquisition of Pint PharmaSobi paid USD 62 million at closing, with up to USD 40 million in additional payments linked to sales milestones. [1]
- 16 Oct 2026CHMP recommended Tryngolza for severe hypertriglyceridaemiaThe CHMP adopted a positive opinion on extending the Tryngolza (olezarsen) indication to adults with severe hypertriglyceridaemia and fasting triglycerides of at least 10 mmol/L, as an adjunct to diet in combination with other lipid-lowering therapies. Sobi expects the European Commission decision in the fourth quarter of 2026. [3]
- 27 Oct 2026Q3 report raised the revenue outlook for 2026Revenue was 9,124 million SEK (7,776), up 16 per cent at constant exchange rates. Adjusted EBITA was 4,087 million SEK (3,672), a margin of 45 per cent (47), and adjusted earnings per share after dilution 6.89 SEK (6.05). Sobi now expects revenue growth of high-teens to low-20s per cent at constant exchange rates for 2026 (previously mid- to high-teens per cent); the adjusted EBITA margin outlook of mid- to high-30s per cent is unchanged. Chief Executive Guido Oelkers, whose departure Sobi announced during the third quarter, remains in the role until the end of January 2027 at the latest. [1]
- 28 Oct–3 Nov 2026Eight houses raised their share price targetsPareto Securities, Nordea, BNP Paribas, DNB Carnegie and HC Wainwright revised on 28 October, SB1 Markets and Danske Bank on 29 October and Berenberg on 3 November. [6,7,8,9,10,11,12,13]
- 29 Oct 2026Detailed phase III data for pozdeutinurad in goutSobi reported the topline result from the REDUCE-2 trial in the second quarter. In the detailed data from the pivotal study of 811 patients, 69.2 per cent on 75 mg and 56.6 per cent on 50 mg reached serum urate below 6 mg/dL at month 6, against 8.1 per cent on placebo. The data are presented as a late-breaking abstract at ACR Convergence on 11 November 2026. [1,4]
- 29 Oct 2026Börje Ekholm proposed as Chair of the BoardThe Nomination Committee proposes Börje Ekholm as Chair at the 2027 Annual General Meeting; David Meek does not stand for re-election. [5]
Takeaways from the panel
All analyst houses with Buy ratings have a target share price above the 6 November close of 498.20 SEK, while all houses with a Hold rating sit below it.
The Buy side runs from 525 to 600 SEK, 5.4 to 20.4 per cent above the close, while the Hold side spans from 475 to 484 SEK, 4.7 to 2.9 per cent below the close. [6,7,8,9,10,11,12,13]
On 22 October, Nordea lowered its target from 500 to 450 SEK and changed its rating from Buy to Hold. [16] After the report, it raised its target to 480 SEK, still 20 SEK below its target before the cut, and reiterated Hold. [7]
Similarly, SB1 Markets lowered its target from 515 to 495 SEK and kept Buy. [17] Following the report, SB1 raised to a higher level of 525 SEK. [11]
Numbered sources
- Sobi Q3 2026 report: Underpinning a strong growth momentum
- Swedish Orphan Biovitrum (SOBI), closing price 6 November 2026
- Sobi receives positive CHMP opinion for TRYNGOLZA (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
- Late-breaking phase III REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad
- Börje Ekholm is proposed as new Chair of the Sobi Board of Directors
- Pareto Securities upgrades Sobi to Buy (Hold), target 530 SEK (480)
- Nordea raises Sobi target to 480 SEK (450), reiterates Hold
- BNP Paribas raises Sobi target to 575 SEK (565), reiterates Outperform
- DNB Carnegie raises Sobi target to 484 SEK (474), reiterates Hold
- HC Wainwright raises Sobi target to 600 SEK (575), reiterates Buy
- SB1 Markets raises Sobi target to 525 SEK (495), reiterates Buy
- Danske Bank raises Sobi target to 475 SEK (466), reiterates Hold
- Berenberg raises Sobi target to 600 SEK (570), reiterates Buy
- Barclays raises Sobi target to 590 SEK (530), reiterates Overweight
- Arctic initiates coverage of Sobi with Buy and a target of 551.24 SEK
- Nordea downgrades Sobi to Hold (Buy), target 450 SEK (500)
- SB1 Markets reiterates Buy on Sobi, lowers target to 495 SEK (515)
How the report was compiled
Selection The panel lists the ten sell-side houses whose latest target on Sobi was published within 90 days of the snapshot date and could be matched to an individual dated notice, each at its latest target and rating. Mean, median and range are computed across the eight houses whose targets were set after Sobi's interim report for July–September 2026, published on 27 October 2026. [1] That window is shorter than the 90 days to the snapshot date and therefore applies. Barclays and Arctic Securities set their targets before the report; they are thus excluded from the aggregates. The latest notice in the panel is Berenberg's revision of 3 November 2026, and no house published a new target on Sobi between then and the snapshot. Coverage of Sobi is wider than the panel shown: houses whose latest target is older than 90 days, or could not be matched to a citable notice, are not listed, and independent research sold to end investors is outside the panel.
Price and valuation basis All figures are referenced against the Sobi closing price of 498.20 SEK on Nasdaq Stockholm on 6 November 2026. [2] Market capitalisation of 173.4 bn SEK is calculated on 348,004,559 shares at 30 September 2026, excluding the 9,631,955 shares held in treasury. [1] The price-earnings ratio of 24.2 is stated on trailing twelve months adjusted earnings per share after dilution of 20.57 SEK: 16.79 SEK for 2025, less 11.14 SEK for January–September 2025, plus 14.92 SEK for January–September 2026, all three taken from the Q3 report and its comparative columns. [1] This is the same basis as BioStock's Sobi analysis of August 2026. All houses publish in Swedish kronor and no currency conversion has been applied.
Ratings Buy, Hold and Sell are normalised from each house's own scale: Buy, Overweight, Outperform and Accumulate to Buy; Hold, Neutral and Market Perform to Hold; Sell, Underweight, Reduce and Underperform to Sell. The recommendation breakdown counts each of the eight included houses once, at the rating published with its target.
Take this analysis with you
A branded consensus report on the eight houses that revised after the Q3 report, ready to share or print.
Download PDF